Abrahim Al‐Mamgani

ORCID: 0000-0003-0748-6640
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Head and Neck Cancer Studies
  • Head and Neck Surgical Oncology
  • Advanced Radiotherapy Techniques
  • Prostate Cancer Treatment and Research
  • Prostate Cancer Diagnosis and Treatment
  • Ear and Head Tumors
  • Lung Cancer Diagnosis and Treatment
  • Dysphagia Assessment and Management
  • Cancer Immunotherapy and Biomarkers
  • Medical Imaging Techniques and Applications
  • Salivary Gland Tumors Diagnosis and Treatment
  • Radiomics and Machine Learning in Medical Imaging
  • Colorectal and Anal Carcinomas
  • Brain Metastases and Treatment
  • Oral health in cancer treatment
  • Peptidase Inhibition and Analysis
  • Radiopharmaceutical Chemistry and Applications
  • Tumors and Oncological Cases
  • Tracheal and airway disorders
  • Pancreatic and Hepatic Oncology Research
  • Nutrition and Health in Aging
  • Nonmelanoma Skin Cancer Studies
  • Effects of Radiation Exposure
  • Interpreting and Communication in Healthcare
  • Patient-Provider Communication in Healthcare

The Netherlands Cancer Institute
2016-2024

Oncode Institute
2016-2024

Erasmus MC
2007-2011

Erasmus MC Cancer Institute
2009

Surgery for locoregionally advanced head and neck squamous cell carcinoma (HNSCC) results in 30‒50% five-year overall survival. In IMCISION (NCT03003637), a non-randomized phase Ib/IIa trial, 32 HNSCC patients are treated with 2 doses (in weeks 1 3) of immune checkpoint blockade (ICB) using nivolumab (NIVO MONO, n = 6, Ib arm A) or plus single dose ipilimumab (COMBO, 26, 6 B, 20 IIa) prior to surgery. Primary endpoints feasibility resect no later than week (phase Ib) primary tumor...

10.1038/s41467-021-26472-9 article EN cc-by Nature Communications 2021-12-22

Abstract Background Human papillomavirus (HPV)‐positive oropharyngeal squamous cell carcinoma (OPSCC) have better prognosis and treatment response compared to HPV‐negative OPSCC. This study aims noninvasively predict HPV status of OPSCC using clinical and/or radiological variables. Methods Seventy‐seven magnetic resonance radiomic features were extracted from T1‐weighted postcontrast images the primary tumor 153 patients. Logistic regression models created status, determined with...

10.1002/hed.26505 article EN cc-by Head & Neck 2020-10-07

Background The efficacy of rehabilitative exercises for chronic dysphagia treatment in head and neck cancer survivors has not been studied extensively is ambiguous. Methods A prospective clinical phase II study using an intensive strength training program was carried out 17 with dysphagia. Both swallow nonswallow were performed 6-8 weeks a newly developed tool allowing progressive muscle overload, including chin tuck, jaw opening, effortful exercises. Outcome parameters feasibility,...

10.1002/hed.24710 article EN Head & Neck 2017-08-02

Conclusions: Although organ preservation can be achieved with chemoradiation protocols for laryngeal or pharyngeal cancers, salvage surgery is accompanied by high complication rates. Objectives: To determine the rate of complications associated after and cancers. Methods: A multicenter retrospective study was performed 24 patients treated total laryngectomy combined partial pharyngectomy between 1995 2004 who had previously been chemoradiation. The main outcome measures were early late...

10.3109/00016489.2011.617779 article EN Acta Oto-Laryngologica 2011-10-25

Chemoradiation (CRT) is a valuable treatment option for advanced hypopharyngeal squamous cell cancer (HSCC). However, long-term toxicity and quality of life (QOL) scarcely reported. Therefore, efficacy, acute toxic effects, QOL CRT HSCC were evaluated,using retrospective study post-treatment questionnaires. in tertiary hospital setting. Analysis was performed 73 patients that had been treated with CRT. Toxicity rated using the CTCAE score list. questionnaires EORTC QLQ-C30, QLQ-H&N35, VHI...

10.1007/s00405-011-1694-8 article EN cc-by-nc European Archives of Oto-Rhino-Laryngology 2011-07-07

Abstract Background The majority of patients with head and neck squamous cell carcinoma (HNSCC) receive bilateral elective nodal irradiation (ENI), in order to reduce the risk regional failure. Bilateral ENI, as compared unilateral is associated higher incidence acute late radiation-induced toxicity subsequent deterioration quality life. Increasing evidence that contralateral failure (cRF) lateralized HNSCC very low (< 10%) suggests it can be justified treat selected unilaterally. This...

10.1186/s12885-019-6331-8 article EN cc-by BMC Cancer 2019-11-14

Background and purpose: Primary radiotherapy is often preferred for early-stage cancer of the nasal vestibule (CNV), combining high disease control with preservation anatomy.However, due to practice variation an absence comparative trials, no consensus exists on preference brachytherapy (BT) or external beam (EBRT).We compared these modalities in terms control, nose rates toxicity.Materials methods: Medical records 225 patients T1-T2 squamous cell carcinoma treated 3D image-guided primary...

10.1016/j.radonc.2021.08.018 article EN cc-by Radiotherapy and Oncology 2021-09-03

Abstract Background Sarcopenia might be a relevant lead for optimization of the condition patients with head and neck cancer (HNC) before chemoradiotherapy (CRT) to prevent long‐term functional swallowing impairment, such as feeding tube dependency. Methods Regression analyses were performed assess association between skeletal muscle mass index (SMI), measure sarcopenia, prolonged (>90 days) dependency in 128 HNC treated primary CRT. Results Sixty‐one (48%) became tube‐dependent. Lower...

10.1002/hed.25938 article EN Head & Neck 2019-08-31

Abstract Background Low skeletal muscle mass (SMM) is an adverse prognostic factor for chemotherapy dose‐limiting toxicity (CDLT). In patients with locally advanced head and neck squamous cell carcinoma (HNSCC) undergoing chemoradiotherapy (CRT), low SMM a predictor CDLT. We aimed to validate these findings. Methods Consecutive LA‐HNSCC treated primary CRT high‐dose cisplatin were retrospectively included. was measured on pre‐treatment CT‐imaging. A cumulative dose below 200 mg/m 2 defined...

10.1002/hed.26919 article EN cc-by Head & Neck 2021-10-29

Background and purposeXerostomia remains a common side effect of radiotherapy (RT) for patients with head neck (H&N) cancer despite advancements in treatment planning delivery. Secretory salivary gland cells express the prostate-specific membrane antigen (PSMA), show significant uptake on PET scans using 68Ga/18F-PSMA-ligands. We aimed to objectively quantify dose–response glands RT PSMA PET.Methods materials28H&N received 70 Gy 35 fractions over 7 weeks. PET/CT was acquired at baseline...

10.1016/j.radonc.2022.10.038 article EN cc-by-nc-nd Radiotherapy and Oncology 2022-11-08
Coming Soon ...